# Proteon Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/proteon-therapeutics

- Industry: Biotechnology
- Headquarters: Waltham, US
- Website: www.proteontherapeutics.com
- Total disclosed funding: $116M
- Latest round: Series D (May 16, 2014)
- Investors on record: 13

## About

Proteon Therapeutics focuses on developing innovative therapies for unmet medical needs, particularly in the areas of cancer treatment and parenteral nutrition support. The company aims to address significant health challenges through its specialized product offerings.Proteon Therapeutics was founded in 2001 and is headquartered in Waltham, US. The company is dedicated to advancing therapies for conditions such as non-muscle invasive bladder cancer and choline deficiency. The company raised USD 61.1 million in its IPO on October 21, 2014, bringing the total amount raised to USD 61.1 million.Proteon Therapeutics specializes in developing innovative therapies for unmet medical needs. Its primary products include TARA-002, an investigational cell therapy aimed at treating non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, which addresses choline deficiency in patients requiring parenteral support. Both products are primarily targeted at healthcare providers and institutions across the United States, with TARA-002 also approved for use in Japan and Taiwan.In the most recent year of 2018, Proteon Therapeutics reported no revenue, with an EBITDA of -USD 48.14 mn. The company generates revenue through partnerships with healthcare providers, focusing on the direct sale of its therapies to hospitals and clinics that treat specific patient populations.Proteon Therapeutics plans to leverage its recent IPO funding of USD 61.1 million to further develop its product pipeline and expand its market presence. The company aims to enhance its product offerings and explore new geographic markets by 2024. The funding will support these initiatives as Proteon Therapeutics continues to address critical healthcare needs.

## Funding rounds

- Series D, May 16, 2014, $45M — Abingworth, Intersouth Partners, Prism Venture Management, TVM Capital Life Science, Skyline Ventures, Vectis Capital, Devon Park Bioventures, Bessemer Venture Partners, MPM BioImpact, Deerfield Management, Pharmstandard International S.A.
- Series C, Aug 2, 2011, $15M — Intersouth Partners, Prism Venture Management, TVM Capital Life Science, Skyline Ventures, Devon Park Bioventures, Bessemer Venture Partners, MPM BioImpact
- Series B, May 28, 2009, $2M — Intersouth Partners, Prism Venture Management, TVM Capital Life Science, Skyline Ventures, Devon Park Bioventures, Bessemer Venture Partners
- Series B, Mar 3, 2009, $19M — Intersouth Partners, Prism Venture Management, TVM Capital Life Science, Skyline Ventures, BPEA Private Equity, Vectis Capital, MPM BioImpact
- Series A, Aug 29, 2007, $12M — Intersouth Partners, Prism Venture Management, Skyline Ventures, TVM Capital
- Series A, Feb 21, 2007, $23M — Intersouth Partners, Prism Venture Management, Skyline Ventures, TVM Capital

## Investors

- Intersouth Partners (https://capitalatlas.ai/funds/intersouth-partners) — Series A, Series B, Series C, Series D
- Prism Venture Management (https://capitalatlas.ai/funds/prism-venture-management) — Series A, Series B, Series C, Series D
- Skyline Ventures (https://capitalatlas.ai/funds/skyline-ventures) — Series A, Series B, Series C, Series D
- TVM Capital (https://capitalatlas.ai/funds/tvm-capital) — Series A
- TVM Capital Life Science (https://capitalatlas.ai/funds/tvm-capital-life-science) — Series B, Series C, Series D
- BPEA Private Equity (https://capitalatlas.ai/funds/bpea-private-equity) — Series B
- Vectis Capital (https://capitalatlas.ai/funds/vectis-capital) — Series B, Series D
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series B, Series C, Series D
- Devon Park Bioventures (https://capitalatlas.ai/funds/devon-park-bioventures) — Series B, Series C, Series D
- Bessemer Venture Partners (https://capitalatlas.ai/funds/bessemer-venture-partners) — Series B, Series C, Series D
- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series D
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series D
- Pharmstandard International S.A. — Series D